Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 10, 2026, 2:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Phase 2 Condition 3 Clear all
Completed Phase 2 Interventional

Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD

NCT00648245
View directory record Official record
Conditions
COPD, Chronic Obstructive Pulmonary Disease
Interventions
BIO-11006 Inhalation Solution, Placebo, BIO-11006
Drug
Lead sponsor
BioMarck Pharmaceuticals, Ltd.
Industry
Eligibility
45 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
14
States / cities
Glendale, Arizona • Los Angeles, California • Bay Pines, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2011 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 2 Interventional

Docetaxel and Capecitabine in Treating Patients With Metastatic Cancer of the Stomach or Gastroesophageal Junction

NCT00054457
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
capecitabine, docetaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
28
States / cities
Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional

Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA)

NCT00217373
View directory record Official record
Conditions
Adult Solid Neoplasm
Interventions
Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine, Recombinant Interferon Alfa-2b, Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine, Sargramostim
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 19, 2015 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Not applicable Interventional

Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases

NCT00376922
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Pain, Precancerous Condition, Psychosocial Effects of Cancer and Its Treatment
Interventions
music therapy
Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects

NCT06593457
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IP, Matching Placebo
Drug
Lead sponsor
Nurix Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 13, 2025 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 3 Interventional Results available

Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

NCT00322101
View directory record Official record
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
Interventions
total-body irradiation, allogeneic hematopoietic stem cell transplantation, cyclophosphamide, mycophenolate mofetil, busulfan, cyclosporine, fludarabine phosphate, peripheral blood stem cell transplantation, nonmyeloablative allogeneic hematopoietic stem cell transplantation, laboratory biomarker analysis, cytogenetic analysis, flow cytometry, fluorescence in situ hybridization, pharmacological study, polymorphism analysis, tacrolimus, methotrexate
Radiation · Procedure · Drug + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Denver, Colorado • Altanta, Georgia • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional Results available

Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection

NCT02185794
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Voxilaprevir, Placebo to match voxilaprevir, SOF/VEL
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
10
States / cities
Costa Mesa, California • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 10, 2026, 2:46 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

NCT02446457
View directory record Official record
Conditions
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
Interventions
Laboratory Biomarker Analysis, Lenalidomide, Pembrolizumab, Rituximab
Other · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis

NCT00761657
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Roxadustat, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
34
States / cities
Peoria, Arizona • Tempe, Arizona • Los Angeles, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2021 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

NCT02406742
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic, B-Cell
Interventions
CC-122, Ibrutinib, Obinutuzumab
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 79 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
8
States / cities
La Jolla, California • Boston, Massachusetts • Hackensack, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 19, 2021 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer

NCT00003594
View directory record Official record
Conditions
Colorectal Cancer
Interventions
irinotecan, fluorouracil, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,691 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
430
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 261 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2020 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Not applicable Interventional

Early Detection and Prevention of Mild Cognitive Impairment Due to Cerebrovascular Disease

NCT01924312
View directory record Official record
Conditions
Cerebrovascular Disease, Mild Cognitive Impairment
Interventions
Heart Health Intervention
Behavioral
Lead sponsor
Gregory Jicha, 323-5550
Other
Eligibility
55 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 2 Interventional

Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia

NCT00968851
View directory record Official record
Conditions
Schizophrenia, Central Nervous System Diseases, Cognition
Interventions
EVP-6124, Placebo
Drug
Lead sponsor
FORUM Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
14
States / cities
Glendale, California • Oceanside, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 10, 2026, 2:46 AM EDT
Active, not recruiting Phase 1 Interventional

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

NCT05334329
View directory record Official record
Conditions
Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Antineoplastic Immune Cell, Atezolizumab, Biospecimen Collection, Cyclophosphamide, Fludarabine
Biological · Procedure · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Active, not recruiting Phase 2 Interventional

An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT06991556
View directory record Official record
Conditions
Metastatic Hormone-sensitive Prostate Cancer
Interventions
JSB462, Abiraterone, Enzalutamide
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
167 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
21
States / cities
La Jolla, California • Santa Monica, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies

NCT02118337
View directory record Official record
Conditions
Select Advanced Malignancies, Kidney Cancer, Clear Cell Renal Cell Carcinoma
Interventions
MEDI0680, Durvalumab, Nivolumab
Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
13
States / cities
Los Angeles, California • Tampa, Florida • Overland Park, Kansas + 10 more
Source: ClinicalTrials.gov public record
Updated May 31, 2021 · Synced Sep 10, 2026, 2:46 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Targeting Language-specific and Executive-control Networks With Transcranial Direct Current Stimulation in Logopenic Variant PPA

NCT03887481
View directory record Official record
Conditions
Logopenic Progressive Aphasia, Primary Progressive Aphasia
Interventions
High-definition active tDCS (HD-tDCS) + "Repeat After Me" (RAM) Treatment, Sham + "Repeat After Me" (RAM) Treatment
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
50 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 1 Interventional

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

NCT00620295
View directory record Official record
Conditions
Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
bortezomib, gemcitabine hydrochloride
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
70 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 2 Interventional

Radiation Therapy and Paclitaxel, Carboplatin, and Fluorouracil Followed by Esophagectomy in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction

NCT00022139
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
35
States / cities
Chanute, Kansas • Dodge City, Kansas • El Dorado, Kansas + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

NCT00448201
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
Interventions
anti-thymocyte globulin, sargramostim, therapeutic allogeneic lymphocytes, busulfan, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
10 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Not applicable Interventional

Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT00079222
View directory record Official record
Conditions
Cancer
Interventions
itraconazole, voriconazole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 2, 2020 · Synced Sep 10, 2026, 2:46 AM EDT
Active, not recruiting Phase 1 Interventional Results available

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

NCT02589522
View directory record Official record
Conditions
Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions
Berzosertib, Quality-of-Life Assessment, Therapeutic Conventional Surgery, Whole-Brain Radiotherapy
Drug · Other · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
9
States / cities
Duarte, California • Sacramento, California • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Not applicable Interventional Results available

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

NCT01720602
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
vorinostat, anastrozole, letrozole, exemestane, positron emission tomography, F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, laboratory biomarker analysis
Drug · Procedure · Radiation + 1 more
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 10, 2026, 2:46 AM EDT
Completed Phase 2 Interventional Results available

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

NCT03106077
View directory record Official record
Conditions
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, Folate Receptor Alpha Positive, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Mirvetuximab Soravtansine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 1, 2020 · Synced Sep 10, 2026, 2:46 AM EDT